Table 2.

Cumulative incidence [with 95% confidence interval] of acute and chronic GvHD, NRM, relapse, and OS according to pre-transplantation obesity and diabetes status.

Outcome	Control group (N = 29,208)	Obesity (N = 5228)	Diabetes (N = 1415)	Obesity + Diabetes (N = 688)
Acute GvHD grade II–IV (at day +100)	27.3% [26.8–27.9]	26.6% [25.4–27.9]	25.7% [23.4–28.0]	25.8% [22.5–29.2]
Chronic GvHD, limited and extensive (at 2 years)	34.4% [33.8–35.0]	34.9% [33.5–36.3]	33.0% [30.4–35.7]	36.6% [32.6–40.6]
Extensive chronic GvHD (at 2 years)	15.8% [15.3–16.2]	15.2% [14.1–16.3]	15.3% [13.3–17.5]	19.0% [15.8–22.4]
NRM (at 1-year)	14.0% [13.6–14.4]	15.5% [14.5–16.5]	23.9% [21.6–26.3]	20.0% [16.9–23.3]
NRM (at 2 years)	16.8% [16.4–17.3]	18.2% [17.1–19.4]	27.9% [25.4–30.4]	24.6% [21.1–28.2]
Relapse (at 1-year)	22.8% [22.3–23.3]	21.8% [20.6–23.0]	23.1% [20.8–25.4]	20.7% [17.5–24.1]
Relapse (at 2 years)	28.7% [28.2–29.3]	28.2% [26.9–29.6]	28.4% [25.8–31.0]	27.7% [24.0–31.5]
OS (at 1-year)	73.2% [72.7–73.7]	73.0% [71.8–74.3]	61.5% [59.0–64.2]	66.9% [63.4–70.7]
OS (at 2 years)	63.6% [63.0–64.2]	63.9% [62.5–65.3]	50.1% [47.4–53.0]	55.0% [51.1–59.2]

GvHD graft-versus-host disease, OS overall survival, NRM non-relapse mortality.